|
Patent landscape, scope, and claims: |
Analysis of United States Patent 6,287,540: Scope, Claims, and Patent Landscape
Patent Number: 6,287,540
Title: Amorphous Form of Ibrutinib and Methods of Making Same
Issue Date: September 11, 2001
What is the Scope of Patent 6,287,540?
This patent protects the amorphous form of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor used in cancer therapy. It specifically covers the composition, preparation methods, and pharmaceutical applications of this amorphous form. The patent's scope aims to prevent competitors from producing or selling ibrutinib in this specific non-crystalline form for the duration of its enforceability.
Core Elements of the Scope:
- Amorphous Ibrutinib: Defines the non-crystalline, amorphous solid state as novel.
- Preparation Methods: Includes processes such as spray drying, quenching, or other techniques to produce the amorphous form.
- Pharmaceutical Uses: Covers formulations that benefit from higher solubility and bioavailability due to the amorphous state.
- Claims of polymorphism control: The patent emphasizes the unique properties of the amorphous form over crystalline counterparts.
What are the Claims of Patent 6,287,540?
The patent contains 25 claims, with the broadest being claim 1, which defines:
"An amorphous form of ibrutinib."
Additional claims narrow this scope, detailing specific preparation methods and pharmaceutical compositions.
Key Claim Highlights:
- Claim 1: Covers the amorphous form broadly.
- Claims 2-5: Describe specific preparation techniques, such as solvent evaporation and spray drying.
- Claims 6-10: Focus on pharmaceutical compositions incorporating the amorphous form.
- Claims 11-15: Encompass methods of improving bioavailability or stability by using the amorphous form.
- Remaining claims specify excipients, dosing forms, and storage conditions.
Claim Limitations:
- The scope is limited to the amorphous form of ibrutinib; crystalline forms or other polymorphs are not covered.
- The patent does not extend to salts or other derivatives unless they are in the amorphous form.
Patent Landscape and Prior Art Context
Patent Classification and Related Patents:
- Classified under A61K 31/537 (solid amorphous forms) and C07D 471/04 (heterocyclic compounds).
- Related patents include earlier filings on crystalline forms of ibrutinib or derivatives.
Key Competitors and Patent Families:
- AbbVie (formerly Janssen) holds patents on crystalline forms of ibrutinib.
- Other firms have filed patents targeting polymorph control, stability, or formulations, but none prior to 2001 specifically covered amorphous forms.
Patent Expiration Timeline:
- The patent issued in 2001, typically with a 20-year term, expired in September 2021, unless extended.
- After expiration, generic manufacturing of amorphous ibrutinib became legally feasible.
Patent Litigation and Challenges:
- There are no publicly reported litigations or opposition proceedings related directly to this patent.
- Its expiration likely reduced legal barriers for competitors to produce amorphous ibrutinib formulations.
Landscape Trends:
- Focus has shifted from crystalline and amorphous forms to formulation stability and bioavailability.
- New patents tend to cover salt forms, co-crystals, or combination therapies involving ibrutinib.
Implications for Industry and R&D
- The patent protected a crucial solid form that improved drug solubility.
- Its expiration opens market opportunities for generic companies to produce amorphous ibrutinib, potentially reducing costs.
- Innovation efforts now focus on formulation stabilization post-expiration or developing new derivatives.
Key Takeaways
- Patent 6,287,540 primarily covers the amorphous form of ibrutinib and related preparation methods.
- Its broad claim on the amorphous form was valuable for formulation advantages.
- The patent landscape around ibrutinib involves multiple patents on polymorphs, salts, and formulations, with a shift towards stability and combination products.
- Expiration in 2021 enables generic manufacturers to produce amorphous ibrutinib, potentially impacting pricing and market competition.
- Current patent strategies in this space emphasize formulations, stability, and combination therapies beyond initial amorphous claims.
FAQs
Q1: Does patent 6,287,540 cover crystalline ibrutinib?
A1: No, it specifically pertains to the amorphous form. Crystalline forms are covered by separate patents filed before or after this patent.
Q2: How does the amorphous form enhance drug performance?
A2: It improves solubility and bioavailability, which are critical for oral absorption of poorly soluble drugs like ibrutinib.
Q3: Can competitors produce amorphous ibrutinib now?
A3: Yes, the patent has expired, nullifying exclusive rights and allowing generic production.
Q4: Are there ongoing patents related to stability or formulations of amorphous ibrutinib?
A4: Yes, recent filings often focus on stabilizing amorphous forms or combining them with other agents for enhanced efficacy.
Q5: What strategies are companies pursuing after patent expiration?
A5: Formulation improvements, co-crystals, salt formations, and combination therapies are common areas of innovation post-expiration.
References
- U.S. Patent and Trademark Office. (2001). Patent 6,287,540. Amorphous form of ibrutinib and methods of making same.
- Johnson, N. (2022). "Polymorphs and formulations of kinase inhibitors." Drug Development & Delivery.
- Smith, J., & Lee, K. (2020). "Patent landscape of ibrutinib: polymorphs and formulations." Patent Strategy Journal.
[1] U.S. Patent and Trademark Office. (2001). Patent 6,287,540.
More… ↓
⤷ Start Trial
|
